Antitumor and antiangiogenic effects of interleukin 12 gene therapy in murine head and neck carcinoma model

Gately, 1992, Regulation of human cytolytic lymphocyte responses by interleukin-12, Cell Immunol, 143, 127, 10.1016/0008-8749(92)90011-D

McKnight, 1994, Effects of IL-12 on helper T cell-dependent immune responses in vivo, J Immunol, 152, 2172, 10.4049/jimmunol.152.5.2172

Trinchieri, 1995, Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity, Annu Rev Immunol, 13, 251, 10.1146/annurev.iy.13.040195.001343

Brunda, 1993, Antitumor and antimetastatic activity of interleukin 12 against murine tumors, J Exp Med, 178, 1223, 10.1084/jem.178.4.1223

Nastala, 1994, Recombinant IL-12 administration induces tumor regression in association with IFN-γ production, J Immunol, 153, 1697, 10.4049/jimmunol.153.4.1697

Verbik, 1996, In vivo therapeutic effects of interleukin-12 against highly metastatic residual lymphoma, Clin Ex Metastasis, 14, 219, 10.1007/BF00053895

Zou, 1995, Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-γ production by anti-tumor T cells, Int Immunol, 7, 1135, 10.1093/intimm/7.7.1135

Strasly, 2001, IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyte-endothelial cell cross-talk, J Immunol, 166, 3890, 10.4049/jimmunol.166.6.3890

Dias, 1998, Multiple molecular and cellular changes associated with tumour stasis and regression during IL-12 therapy of a murine breast cancer model, Int J Cancer, 75, 151, 10.1002/(SICI)1097-0215(19980105)75:1<151::AID-IJC23>3.0.CO;2-I

Voest, 1995, Inhibition of angiogenesis in vivo by interleukin 12, J Natl Cancer Inst, 87, 581, 10.1093/jnci/87.8.581

Tannenbaum, 1996, Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12, J Immunol, 156, 693, 10.4049/jimmunol.156.2.693

Rakhmilevich, 1996, Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors, Proc Natl Acad Sci USA, 93, 6291, 10.1073/pnas.93.13.6291

Leonard, 1997, Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production, Blood, 90, 2541

Atkins, 1997, Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies, Clin Cancer Res, 3, 409

Chen, 1997, Eradication of murine bladder carcinoma by intratumor injection of a bicistronic adenoviral vector carrying cDNAs for the IL-12 heterodimer and its inhibition by the IL-12 p40 subunit homodimer, J Immunol, 159, 351, 10.4049/jimmunol.159.1.351

Myers, 1998, Interleukin-12 gene therapy prevents establishment of SCC VII squamous cell carcinomas, inhibits tumor growth, and elicits long-term antitumor immunity in syngeneic C3H mice, Laryngoscope, 108, 261, 10.1097/00005537-199802000-00019

Coughlin, 1998, Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis, J Clin Invest, 101, 1441, 10.1172/JCI1555

Tahara, 1994, Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo, Cancer Res, 54, 182

Herr, 1996, Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens, J Immunol Methods, 191, 131, 10.1016/0022-1759(96)00007-5

Asai, 2000, Evaluation of the modified ELISPOT assay for gamma interferon production in cancer patients receiving antitumor vaccines, Clin Diagn Lab Immunol, 7, 145, 10.1128/CDLI.7.2.145-154.2000

Meidenbauer, 2000, Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer, Prostate, 43, 88, 10.1002/(SICI)1097-0045(20000501)43:2<88::AID-PROS3>3.0.CO;2-G

Asselin-Paturel, 1999, Transfer of the murine interleukin-12 gene in vivo by a Semliki Forest virus vector induces B16 tumor regression through inhibition of tumor blood vessel formation monitored by Doppler ultrasonography, Gene Ther, 6, 606, 10.1038/sj.gt.3300841

Mendiratta, 1999, Intratumoral delivery of IL-12 gene by polyvinyl polymeric vector system to murine renal and colon carcinoma results in potent antitumor immunity, Gene Ther, 6, 833, 10.1038/sj.gt.3300891

Dow, 1999, Intravenous cytokine gene delivery by lipid-DNA complexes controls the growth of established lung metastases, Hum Gene Ther, 10, 2961, 10.1089/10430349950016375

Puisieux, 1998, Canarypox virus-mediated interleukin 12 gene transfer into murine mammary adenocarcinoma induces tumor suppression and long-term antitumoral immunity, Hum Gene Ther, 9, 2481, 10.1089/hum.1998.9.17-2481

Yao, 1999, Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12, Blood, 93, 1612, 10.1182/blood.V93.5.1612

Chan, 1991, Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers, J Exp Med, 173, 869, 10.1084/jem.173.4.869

Frucht, 2001, IFN-gamma production by antigen-presenting cells: mechanisms emerge, Trends Immunol, 22, 556, 10.1016/S1471-4906(01)02005-1

Schreiber, 1992, The structure and function of interferon-gamma receptors, Int J Immunopharmacol, 14, 413, 10.1016/0192-0561(92)90171-G

Tsung, 1997, IL-12 induces T helper 1-directed antitumor response, J Immunol, 158, 3359, 10.4049/jimmunol.158.7.3359

Yu, 1997, IL-12-induced tumor regression correlates with in situ activity of IFN-gamma produced by tumor-infiltrating cells and its secondary induction of anti-tumor pathways, J Leukoc Biol, 62, 450, 10.1002/jlb.62.4.450

Tsukuda, 1993, Autologous tumor cell killing activity of tumor-associated lymphocytes in patients with head and neck carcinomas, Biotherapy, 6, 155, 10.1007/BF01877429